Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1, a self-developed and ...
Akeso, Inc.: Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment ...
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: It has been quietly happening in the ...
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer ...
中国日报网17h
Chinese company's drug beats world's biggest-selling medicine: media
Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication ...
finanzen2d
Akeso's Partner Summit, Pfizer Collaborate To Evaluate Ivonescimab In Solid Tumor Settings
Akeso Inc. has announced that Summit Therapeutics Inc. (SMMT), its partner for ivonescimab, has entered into a clinical trial ...
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program
Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.
Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good morning and welcome to Summit Therapeutics Fourth Quarter and Year End 2024 Earnings and Update Call. All participants will be in ...
Medindia13d
Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Ra and ST2 for Respiratory and Skin Diseases
HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a ...